Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | PI4KA | P42356 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | EDNRA | P25101 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2345590 | 0.79 | PSIP1 (0.34) | CA12CA1CA2CA4CA6 | |
| SCHEMBL3640748 | 0.78 | TET2 (0.40) | CA12CA1CA2CA4CA6 | |
| SCHEMBL713957 | 0.78 | CA12 (0.36) | CA12CA1CA2CA4CA6 | |
| SCHEMBL24899890 | 0.78 | POLB (0.44) | CA12CA1CA2CA4CA6 | |
| SCHEMBL26107943 | 0.77 | PI4KB (0.55) | PIK3CDPIP5K1CPIK3CBPI4KAPIK3CG | |
| SCHEMBL2572656 | 0.76 | ENPP2 (0.43) | PIK3CDPIP5K1CPIK3CBPI4KAPIK3CG | |
| SCHEMBL2645412 | 0.76 | PIK3CD (0.40) | PIK3CDPIP5K1CPIK3CBPI4KAPIK3CG | |
| SCHEMBL486163 | 0.76 | CCR1 (0.46) | PIK3CDPIP5K1CPIK3CBPI4KAPIK3CG | |
| SCHEMBL24899889 | 0.75 | CA12 (0.32) | CA12CA1CA2CA4CA6 | |
| SCHEMBL1492547 | 0.74 | CA12 (0.67) | PIK3CDPIP5K1CPIK3CBPI4KAPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12564636-B2 | Pnictogen-containing heterocyclic compounds and their use | UNIVERSITY OF RHODE ISLAND BOARD OF TRUSTEES (US) | 2026-03-03 | — | — | US | disclosed |
| US-20240285772-A1 | PNICTOGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE | COLGATE UNIVERSITY | 2024-08-29 | — | — | US | disclosed |
| WO-2023191953-A1 | PNICTOGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE | UNIVERSITY OF RHODE ISLAND BOARD OF TRUSTEES (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2021041866-A1 | SMALL MOLECULE AGONISTS OF MUCOLIPIN 1 AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-03-04 | — | — | WO | disclosed |
| EP-2847196-B1 | NEW 2,3-DIHYDRO-FURO[2,3-C]PYRIDINES, THEIR USE AS MODULATORS OF THE G-PROTEIN-COUPLED RECEPTOR GPR119 AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | BOEHRINGER INGELHEIM INT (DE) | 2017-10-25 | — | — | EP | disclosed |
| CN-1989115-B | Oxazole derivatives as histamine H3 receptor drugs and preparation and pharmaceutical use thereof | LILLY CO ELI | 2012-03-21 | — | — | CN | disclosed |
| US-7666871-B2 | 3-Methyl-6-(4-{5-methyl-4-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-oxazol-2-yl}-phenyl)-pyridazine; for treatment of obesity, cognitive deficiencies, narcolepsy | ELI LILLY AND COMPANY (US) | 2010-02-23 | — | — | US | disclosed |
| US-7666871-B2 | 3-Methyl-6-(4-{5-methyl-4-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-oxazol-2-yl}-phenyl)-pyridazine; for treatment of obesity, cognitive deficiencies, narcolepsy | ELI LILLY AND COMPANY (US) | 2010-02-23 | — | — | US | disclosed |
| US-7666871-B2 | 3-Methyl-6-(4-{5-methyl-4-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-oxazol-2-yl}-phenyl)-pyridazine; for treatment of obesity, cognitive deficiencies, narcolepsy | ELI LILLY AND COMPANY (US) | 2010-02-23 | — | — | US | disclosed |
| EP-1786790-B1 | OXAZOLE DERIVATIVES AS HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20070197604-A1 | Oxazole derivatives as histamine h3 receptor agents,preparation and therapeutic uses | ELI LILLY AND COMPANY | 2007-08-23 | — | — | US | disclosed |
| US-20070197604-A1 | Oxazole derivatives as histamine h3 receptor agents,preparation and therapeutic uses | ELI LILLY AND COMPANY | 2007-08-23 | — | — | US | disclosed |
| US-20070197604-A1 | Oxazole derivatives as histamine h3 receptor agents,preparation and therapeutic uses | ELI LILLY AND COMPANY | 2007-08-23 | — | — | US | disclosed |
| CN-1989115-A | * azole derivatives as histamine H3 receptor agents, their preparation and therapeutic use | LILLY CO ELI (US) | 2007-06-27 | — | — | CN | disclosed |
| EP-1786790-A1 | OXAZOLE DERIVATIVES AS HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006019833-A1 | OXAZOLE DERIVATIVES AS HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197604-A1 | Oxazole derivatives as histamine h3 receptor agents,preparation and therapeutic uses | HCRTR1, HRH3, HCRTR2 | PIK3CD 2191/4885PIP5K1C 1802/4885PIK3CB 2887/4885 |
| US-12564636-B2 | Pnictogen-containing heterocyclic compounds and their use | CBR1, PNPO, NOX3 | PIK3CD 2691/4885PIP5K1C 2989/4885PIK3CB 2149/4885 |
| US-20240285772-A1 | PNICTOGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE | PYGL, UGT2B7, CYP2E1 | PIK3CD 4091/4885PIP5K1C 3694/4885PIK3CB 2834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.